恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

交易中 10-20 09:35:57

47.520

-0.080

-0.17%

最高48.380	最低47.340	成交量14.04万
今开47.600	昨收47.600	日振幅2.18%
总市值3,154亿	流通市值122.60亿	总股本66.37亿
成交额672.04万	换手率0.05%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":47.52,"timestamp":1792460154924,"preClose":47.6,"halted":0,"volume":140388,"delay":0,"changeRate":-0.0016806722689075271,"floatShares":258000000,"shares":6637000000,"eps":1.3860089622752563,"marketStatus":"交易中","change":-0.08,"latestTime":"10-20 09:35:57","open":47.6,"high":48.38,"low":47.34,"amount":6720357,"amplitude":0.021849,"askPrice":47.54,"askSize":1200,"bidPrice":47.52,"bidSize":400,"shortable":3,"etf":0,"ttmEps":1.366851499415333,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1792468800000},"marketStatusCode":2,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":47.6,"dividendRate":0.004809,"openAndCloseTimeList":[[1792459800000,1792468800000],[1792472400000,1792483200000]],"volumeRatio":1.796812,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":45.65,"timestamp":1792460155000,"preClose":46.08,"halted":0,"volume":3222600,"delay":0,"premium":"-11.38"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"1148990900","title":"财报前瞻 | 恒瑞医药本季度营收预测暂缺，机构观点以谨慎偏正面为主","url":"https://stock-news.laohu8.com/highlight/detail?id=1148990900","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148990900?lang=zh_cn&edition=full","pubTime":"2026-10-20 09:01","pubTimestamp":1792458075,"startTime":"0","endTime":"0","summary":"恒瑞医药将于2026年10月27日发布最新季度财报，市场关注创新药放量与费用投入权衡对利润的影响。目前未检索到覆盖本季度的公开一致预期口径，未获得恒瑞医药对本季度营收、毛利率、净利润或净利率、调整后每股收益的具体预测及同比数据，原因是公开渠道暂未披露对应指标的细分预期。在截至2026年10月20日的区间内，主流机构对恒瑞医药的态度以谨慎偏正面为主，核心论据集中在创新药放量与高毛利结构对冲集采影响的能力上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | 恒瑞医药本季度营收预测暂缺，机构观点以谨慎偏正面为主","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676502015","title":"恒瑞医药(01276.HK)10月19日斥资940.08万元回购20.36万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2676502015","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676502015?lang=zh_cn&edition=full","pubTime":"2026-10-19 18:15","pubTimestamp":1792404904,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["82843","82846","BK1147","03188","LU0359202008.SGD","03130","82822","83130","02843","07233","LU0359201885.HKD","LU1023057109.AUD","BK1191","01276","BK1610","02823","02822","LU2543165471.USD","02827","02846","82823","LU0359201612.USD","83188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125064899","title":"恒瑞医药10月19日回购20.36万股，涉资约940.08万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125064899","media":"公告速递","labels":[],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125064899?lang=zh_cn&edition=full","pubTime":"2026-10-19 18:12","pubTimestamp":1792404768,"startTime":"0","endTime":"0","summary":"恒瑞医药（股票代码：01276）于2026年10月19日发布公告称，公司当日通过上海证券交易所购回203,600股A股股份，将用于A股员工持股计划，占购回前公司已发行股本约0.003%。本次回购价格区间为每股人民币46.08元至46.21元，合计支付约人民币940.08万元。\n截至回购完成后，公司已发行股份数量约为6,366,084,824股，同时库藏股数量增加至约12,917,450股。公司在公告中表示，相关股份购回已符合法律法规及上市规则的要求。\n本公告由公司执行董事、总经理（总裁）、首席运营官冯佶签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"恒瑞医药10月19日回购20.36万股，涉资约940.08万元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676522773","title":"恒瑞医药于10月16日斥资899.71万元回购19.5万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2676522773","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676522773?lang=zh_cn&edition=full","pubTime":"2026-10-18 19:45","pubTimestamp":1792323900,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与项飙现场对话！\n名额有限，手慢无。让我们共赴可持续之约！【点击报名】恒瑞医药（01276）发布公告，于2026年10月16日斥资899.71万元回购19.5万股A股。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-10-18/doc-inivrzvi7769654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["83130","LU1146622755.USD","07233","LU2328871848.SGD","BK0239","LU2289578879.USD","LU1997244956.HKD","600276","82822","LU1255011170.USD","BK1191","LU0359201885.HKD","02846","03130","LU2097828474.EUR","02822","LU1328615791.USD","LU0405327148.USD","82843","LU1064131003.USD","LU2097828714.EUR","LU1023057109.AUD","399300","BK0012","LU1997245094.SGD","02843","02827","BK1147","LU1820825898.SGD","03188","159982","BK0188","LU0405327494.USD","LU2488822045.USD","BK0196","LU2580892862.HKD","LU2097828557.USD","82846","01276","LU2148510915.USD","LU2543165471.USD","BK1610","LU1064130708.USD","LU1781817850.SGD","82823","BK0183","02823","LU2097828805.USD","83188","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676543627","title":"记者观察|恒瑞医药强在哪儿？","url":"https://stock-news.laohu8.com/highlight/detail?id=2676543627","media":"中国经营报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676543627?lang=zh_cn&edition=full","pubTime":"2026-10-17 10:57","pubTimestamp":1792205860,"startTime":"0","endTime":"0","summary":"一款潜在“大药”能撑起一家公司的市值，也能压垮一家公司的股价。市场最近又重复上演了这个故事，也由此看清了另一条路的真正价值。10月8日，艾力斯（688578.SH）股价跌停。市场真正恐惧的并不是伏美替尼这款药突然失效，而是“一颗药扛起一家公司”的脆弱结构，被全球多中心临床试验的随机性无情撕开。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610173899021192.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610173899021192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU1997245094.SGD","LU1146622755.USD","LU1064130708.USD","LU2488822045.USD","LU1969619763.USD","LU1997244956.HKD","BK0060","LU1781817850.SGD","LU1820825898.SGD","LU2580892789.USD","LU0359201612.USD","LU1064131003.USD","LU2543165471.USD","LU2495084118.USD","LU2097828557.USD","BK0012","BK0028","BK0239","LU0405327494.USD","LU2097828474.EUR","01276","LU0359201885.HKD","LU2097828631.EUR","LU1255011170.USD","LU2289578879.USD","LU1023057109.AUD","LU0359202008.SGD","BK0188","LU1655091616.SGD","BK1191","LU1997245177.USD","LU2097828714.EUR","LU2097828805.USD","LU1580142542.USD","LU0405327148.USD","LU2580892862.HKD","600276","BK0183","LU2328871848.SGD","LU2148510915.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170508239","title":"恒瑞医药回购19.50万股股份，耗资约899.71万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170508239","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170508239?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:08","pubTimestamp":1792141691,"startTime":"0","endTime":"0","summary":"2026年10月16日，江苏恒瑞医药股份有限公司公告称，公司于当日通过上海证券交易所回购A股股份195,000股，占回购前公司已发行股本的0.003%。本次回购的最高和最低每股价格分别为人民币46.33元与人民币45.60元，合计支付价格人民币8,997,100元，折合约899.71万元。公告显示，此次回购完成后，公司已发行股份总数增至6,366,288,424股，库存股份数量上升至12,713,850股。公司确认本次回购严格遵守香港联合交易所有限公司证券上市规则以及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药回购19.50万股股份，耗资约899.71万元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675560883","title":"恒瑞医药(01276)10月16日斥资899.71万元回购19.5万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675560883","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675560883?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:05","pubTimestamp":1792141524,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年10月16日斥资899.71万元回购19.5万股A股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1328615791.USD","LU1997245094.SGD","LU1146622755.USD","03188","02822","LU1064130708.USD","LU2488822045.USD","LU1997244956.HKD","BK0060","07233","LU1781817850.SGD","LU1820825898.SGD","02843","02827","82846","83130","LU1064131003.USD","03130","LU2543165471.USD","82843","LU2097828557.USD","82823","BK0012","BK0028","BK0239","82822","BK0196","LU2097828474.EUR","01276","LU0359201885.HKD","LU2097828631.EUR","LU1255011170.USD","LU2289578879.USD","399300","LU1023057109.AUD","LU0359202008.SGD","BK0188","83188","LU1655091616.SGD","BK1191","LU1997245177.USD","LU1580142542.USD","LU2580892862.HKD","BK1610","600276","02823","BK0183","LU2328871848.SGD","02846","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675530779","title":"贝莱德：在恒瑞医药H股的持股比例升至6.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675530779","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675530779?lang=zh_cn&edition=full","pubTime":"2026-10-15 17:06","pubTimestamp":1792055188,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0359201885.HKD","LU2543165471.USD","LU0359202008.SGD","LU1023057109.AUD","BK1191","01276","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675153377","title":"港股早盘持续走低 恒生科技指数大幅下跌2.94% 联想集团（00992）大跌13.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675153377","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675153377?lang=zh_cn&edition=full","pubTime":"2026-10-15 12:13","pubTimestamp":1792037591,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股三大指数早盘持续走低，截至午间收盘，恒生指数下跌1.47%；国企指数下跌1.51%；恒生科技指数大幅下跌2.94%。国恩科技半日涨13.19%，消息面上，据公告显示，集团预期于2026年前9个月取得归属于上市公司股东的净利润约9.5亿-11亿元，同比增长54.45%-78.84%;扣非净利约9.2亿-10.7亿元，同比增长54.14%-79.27%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200915/NzYyNDljMmIwNjZjMTQ3MTljY2ZkYmY1MDAwNDcwMjMxMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NzYyNDljMmIwNjZjMTQ3MTljY2ZkYmY1MDAwNDcwMjMxMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993772","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0543330483.HKD","LU0164880469.USD","LNVGY","BK1589","LU0672654166.SGD","BK1594","02410","01276","LU0572944931.SGD","LU2543165471.USD","LU0588546209.SGD","06680","01378","LU0320764599.SGD","LU0287142896.SGD","LU0890818403.SGD","LU0128525689.USD","BK1526","KCAI","00992","KURE","LU1785774172.SGD","IE0034224299.USD","TCHI","BK1191","HK0000320223.HKD","LU2328871848.SGD","01258","03993","KTEC","06160","80992","LU0049112450.USD","LU1023057109.AUD","LU1224709979.USD","02600","HK0000320264.USD","LU1969619763.USD","LU0359201612.USD","LU1719994722.HKD","LU0417516902.SGD","LU0862451753.SGD","LU0630314457.HKD","VXUS","09688","BK1513","01208","LU0029875118.USD","03692","03431"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675371541","title":"港股异动 | 恒瑞医药(01276)涨超3% 自研治疗AD药物SHR-3201注射液获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2675371541","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675371541?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:58","pubTimestamp":1792029530,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药(01276)涨超3%，截至发稿，涨2.97%，报47.8港元，成交额4134.91万港元。消息面上，恒瑞医药发布公告，近日，江苏恒瑞医药股份有限公司(以下简称“公司”)子公司北京盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-3201注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-3201注射液是公司自主研发治疗阿尔茨海默病(AD)的药物，可清除患者脑内的疾病生物标志物，延缓患者认知衰退。经查询，国内外尚无同类药物获批上市。截至目前，SHR-3201注射液相关项目累计研发投入约为4,880万元(未经审计)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201885.HKD","VXUS","BK0196","BK4588","LU1655091616.SGD","LU2580892789.USD","BK0012","BK0060","LU1064131003.USD","LU1580142542.USD","LU2097828474.EUR","BMED","BK4585","LU1969619763.USD","LU2543165471.USD","LU1064130708.USD","LU1997245094.SGD","MDTX","LU1997244956.HKD","LU0359201612.USD","LU2488822045.USD","LU1146622755.USD","LU2097828557.USD","BK0188","BK0183","BK0239","KCAI","IBBJ","PSYK","LU2097828805.USD","LU2097828714.EUR","LU2328871848.SGD","LU2148510915.USD","LU2495084118.USD","LU0405327148.USD","LU2580892862.HKD","LU1781817850.SGD","LU1328615791.USD","LU0359202008.SGD","LU0405327494.USD","LU1820825898.SGD","BK1191","LU1255011170.USD","LU1997245177.USD","600276","LU2289578879.USD","LU2097828631.EUR","IBBQ","BK0028","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143186721","title":"异动解读｜恒瑞医药盘中上涨3.14%，回购叠加临床进展提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1143186721","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143186721?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:55","pubTimestamp":1792029332,"startTime":"0","endTime":"0","summary":"10月15日，恒瑞医药盘中上涨3.14%，报47.96港元，成交额3639.68万港元。消息面上，公司10月14日披露当日回购6万股A股，合计支付约269.65万元，回购均价约44.94元，用于员工持股计划；同时公司此前公告，阿尔茨海默病候选药物SHR-3201注射液获准开展临床试验。此外，公司将于10月27日召开董事会审议前三季度业绩。回购、创新管线推进及业绩窗口临近，共同强化市场关注度。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药上涨，回购与临床进展齐发力","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100387805","title":"恒瑞医药10月14日回购6万股，合计支付约269.65万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100387805","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100387805?lang=zh_cn&edition=full","pubTime":"2026-10-14 16:51","pubTimestamp":1791967867,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司于2026年10月14日发布翌日披露报表，披露其当日回购A股相关事项。公司通过上海证券交易所回购A股股份6万股，用作员工持股计划，占回购前已发行股本约0.001%。本次回购股份的单股最高价为人民币45.05元，最低价为人民币44.88元，平均价格约为人民币44.94元，合计支付金额人民币269.65万元。恒瑞医药表示，本次股份购回已经公司董事会批准，并确认遵守相关上市规则及适用法律规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药10月14日回购6万股，合计支付约269.65万元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175227302","title":"恒瑞医药（01276）将于10月27日召开董事会审议2026年前三季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1175227302","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175227302?lang=zh_cn&edition=full","pubTime":"2026-10-14 16:36","pubTimestamp":1791966993,"startTime":"0","endTime":"0","summary":"恒瑞医药（01276）10月14日公告，公司董事会拟于2026年10月27日（星期二）举行会议，届时将审议并批准公司及其附属公司截至2026年9月30日止九个月的季度业绩及其发布事宜。\n公告显示，董事会现由11名成员组成，包括：  \n1. 执行董事：孙飘扬、戴洪斌、冯佶、张连山、江宁军、孙杰平  \n2. 非执行董事：郭丛照  \n3. 独立非执行董事：楼丽广、曾庆生、孙金云、周纪恩\n会议结果及相关业绩数据将在董事会审议后对外公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167836168","title":"恒瑞医药（01276）获准启动阿尔茨海默病候选药物SHR-3201注射液临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1167836168","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167836168?lang=zh_cn&edition=full","pubTime":"2026-10-13 18:15","pubTimestamp":1791886536,"startTime":"0","endTime":"0","summary":"2026年10月13日，江苏恒瑞医药股份有限公司公告称，子公司北京盛迪医药有限公司已收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，获准就SHR-3201注射液开展临床试验。公司介绍，SHR-3201注射液为自主研发的阿尔茨海默病治疗候选药物，可通过清除患者脑内疾病生物标志物来延缓认知衰退。截至目前，SHR-3201项目累计研发投入约4,880万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675449358","title":"恒瑞医药(01276.HK)：SHR-3201注射液获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2675449358","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675449358?lang=zh_cn&edition=full","pubTime":"2026-10-13 18:11","pubTimestamp":1791886303,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0359201885.HKD","LU0359201612.USD","LU0359202008.SGD","LU1023057109.AUD","LU2543165471.USD","BK1191","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675332404","title":"恒瑞医药(600276.SH)：SHR-3201注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2675332404","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675332404?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:04","pubTimestamp":1791882254,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司北京盛迪医药有限公司收到国家药品监督管理局核准签发关于SHR-3201注射液的《药物临床试验批准通知书》，将于近期开展临床试验。申请的适应症：阿尔茨海默病。SHR-3201注射液是公司自主研发治疗AD的药物，可清除患者脑内的疾病生物标志物，延缓患者认知衰退。经查询，国内外尚无同类药物获批上市。截至目前，SHR-3201注射液相关项目累计研发投入约为4,880万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","IBBQ","LU1655091616.SGD","LU0359201885.HKD","LU2097828714.EUR","LU1064130708.USD","BK0196","LU2488822045.USD","BK0028","BK0239","LU2148510915.USD","LU2328871848.SGD","LU2097828805.USD","LU1997245177.USD","LU0405327148.USD","LU1820825898.SGD","LU1580142542.USD","BK0060","IBBJ","LU0359202008.SGD","LU1328615791.USD","MDTX","BMED","PSYK","LU1781817850.SGD","BK0188","LU2097828557.USD","01276","LU1997245094.SGD","LU2097828474.EUR","LU1969619763.USD","BK0183","BK0012","LU2097828631.EUR","LU2580892789.USD","600276","LU0359201612.USD","LU2495084118.USD","LU1146622755.USD","LU0405327494.USD","LU1997244956.HKD","LU2289578879.USD","LU2580892862.HKD","BK1191","LU2543165471.USD","LU1255011170.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161091530","title":"恒瑞医药回购44.26万股A股，耗资约2,000万元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1161091530","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161091530?lang=zh_cn&edition=full","pubTime":"2026-10-13 16:55","pubTimestamp":1791881748,"startTime":"0","endTime":"0","summary":"恒瑞医药于2026年10月13日发布公告，披露在上海证券交易所回购442,600股A股股份，此次回购占公司现有已发行股本约0.007%，所回购股份将作为库存股持有。本次回购价格区间介于每股人民币44.80元至45.55元，总计支付约1,999.95万元人民币，折合约2,000万元人民币。本次回购完成后，公司已发行股本为6,366,543,424股，库藏股数量增至12,458,850股，公司的已发行股本总数仍为6,379,002,274股。公司在公告中确认，其已遵守香港联交所证券上市规则及相关法律法规的规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药回购44.26万股A股，耗资约2,000万元人民币","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675833239","title":"恒瑞医药(01276.HK)10月13日斥资1999.95万元回购44.26万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675833239","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675833239?lang=zh_cn&edition=full","pubTime":"2026-10-13 16:52","pubTimestamp":1791881556,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03188","02822","07233","02843","02827","82846","83130","LU0359201612.USD","03130","LU2543165471.USD","82843","82823","BK1147","82822","01276","LU0359201885.HKD","LU1023057109.AUD","LU0359202008.SGD","83188","BK1191","BK1610","02823","02846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675338091","title":"公募首份三季报出炉，南方港股医药大幅加仓凯莱英、药明康德、恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2675338091","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675338091?lang=zh_cn&edition=full","pubTime":"2026-10-13 12:19","pubTimestamp":1791865173,"startTime":"0","endTime":"0","summary":"10月13日，证监会官网披露显示，南方港股医药行业混合发布2026年第三季度报告，这也是公募基金行业首份三季报。从该基金发布的季报来看，A、C份额季内净值增长率分别达到18.49%、17.73%，季内大幅加仓了凯莱英、药明康德、恒瑞医药等个股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610133893966047.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610133893966047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0572944931.SGD","LU2580892862.HKD","BK0196","02359","LU1781817850.SGD","LU2125910500.SGD","LU0052750758.USD","LU0359202008.SGD","LU1997245177.USD","603259","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU1064131003.USD","LU0348766576.USD","BK0183","LU2543165471.USD","600276","LU1934453819.USD","01276","LU1255011170.USD","LU1979443071.USD","LU0348767384.USD","LU2097828474.EUR","LU2097828631.EUR","LU1969619763.USD","BK1191","LU2580892789.USD","KURE","LU2242644610.SGD","BK1576","LU1328615791.USD","LU1580142542.USD","BK1141","002821","159718","LU1046422090.SGD","LU1146622755.USD","LU0405327494.USD","LU1808992512.USD","BK0012","LU1820825898.SGD","IE00B543WZ88.USD","LU2289578879.USD","LU1997245094.SGD","06821","LU0456842615.SGD","LU1251922891.USD","LU1655091616.SGD","BK0028","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674720768","title":"9股今日获机构买入评级 6股上涨空间超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674720768","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674720768?lang=zh_cn&edition=full","pubTime":"2026-10-12 18:55","pubTimestamp":1791802500,"startTime":"0","endTime":"0","summary":"9只个股今日获机构买入型评级，赛特新材为机构首次关注。证券时报·数据宝统计显示，今日机构研报共发布9条买入型评级记录，共涉及9只个股。今日获机构买入型评级个股中，共有6条评级记录中对相关个股给出了未来目标价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11134,202610123892810467.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11134,202610123892810467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["01276","LU2543165471.USD","BK1191","LU0359202008.SGD","LU1023057109.AUD","LU0359201885.HKD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":0.0439},{"period":"3month","weight":-0.1353},{"period":"6month","weight":-0.2806},{"period":"1year","weight":-0.4175},{"period":"ytd","weight":-0.3296}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}